Navigation Links
Experimental graft-vs.-host disease treatment equivalent to standard care in Phase 3 trial
Date:12/10/2012

An experimental drug combination for preventing graft-versus-host disease (GVHD) was not significantly better than the standard regimen on key endpoints, according to a report of a phase 3 trial at the American Society of Hematology annual meeting.

The combination of two immunosuppressive compounds -- tacrolimus plus sirolimus -- did not provide a statistically significant, GVHD-free survival benefit over the long-used standard of care, tacrolimus plus methotrexate, said researchers from Dana-Farber Cancer Institute who led the multi-center trial.

However, there were some "upsides" of the tacrolimus/sirolimus treatment that could prove advantageous for certain patients, said Corey Cutler, MD, MPH, first author of the report. Among them: patients engrafted slightly more rapidly and suffered much less from mucositis, a common and painful side-effect that causes sores in the mouth and throat.

But there were also "downsides," Cutler said an increased incidence of veno-occlusive disease (blood clots in the liver) and a slight increase in the rate of late-onset GVHD.

"We were a little disappointed in the results, but excited to offer an alternative to the standard of care for the past 25 years," said Cutler, who, along with Joseph Antin, MD, of Dana-Farber, senior author of the report, had led clinical studies of sirolimus beginning in 2000 in hopes that it would promote better survival from GVHD than the standard treatment.

The phase 3 randomized controlled trial was carried out by the Bone and Marrow Clinical Trials Network (BMT CTN) at 26 centers. It enrolled over 300 patients, the majority of whom had acute leukemia in remission. The patients had received stem cell transplants from a matched sibling donor.

The primary endpoint of 114-day acute GVHD-free survival was 67 percent in the tacrolimus/sirolimus group and 62 percent in the tacrolimus/methotrexate group a difference that was not statistically significant
'/>"/>

Contact: Teresa Herbert
teresa_herbert@dfci.harvard.edu
617-632-4090
Dana-Farber Cancer Institute
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Experimental Chemo Combo for Colon Cancer Disappoints
2. Experimental Pill for Multiple Sclerosis Shows Promise
3. Experimental Gel May Help Those With Advanced Parkinsons
4. Experimental Drug Eases Autistic Behaviors in Mice
5. Experimental Drug Helps Fight Some Childhood Cancers, Study Finds
6. Experimental drug improves muscle strength among male cancer patients
7. Experimental Vaccine Seems to Stop Nicotine Addiction in Mice
8. Content Writing King Announces Cancellation Of Experimental Video Creation Process For Their Article Marketing Website
9. Fertility preservation with cryopreservation of ovarian tissue: from experimental to mainstream
10. Experimental drug may extend therapeutic window for stroke
11. Experimental Chemical Helps Blind Mice See
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , ... July 30, 2015 , ... Dale Sky Jones, ... States, will speak at the International Cannabis Professionals Expo held at the Caribe Royal ... The International Cannabis Professionals Expo is the largest medical cannabis expo in ...
(Date:7/30/2015)... ... 2015 , ... Committed to helping the next generation succeed - Mercy College ... to the College’s “My Brother’s Keeper Scholarship.” The President’s signature initiative issues a call ... the support they need to think more broadly about their future. Building on what ...
(Date:7/30/2015)... IL (PRWEB) , ... July 30, 2015 , ... ... according to results from the 2015 Most Wired Survey conducted by Hospitals & Health ... integrated health system owned and operated by The Sisters of the Third Order ...
(Date:7/30/2015)... ... July 30, 2015 , ... Zaca Life ... the go. With no water needed, the refreshing berry-flavored tablets are the perfect ... get the natural ingredients that may help with body detoxification, protection and hydration,” ...
(Date:7/30/2015)... ... July 30, 2015 , ... The American Telemedicine ... Meeting and Tradeshow focused exclusively on telemedicine, telehealth and mHealth. The meeting, expected ... vendors, will take place May 14-17, 2016 in Minneapolis, MN. , ATA’s annual ...
Breaking Medicine News(10 mins):Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 2Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 3Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 4Health News:Finally…First Ever Professional Training Event for Doctors and Nurses Wanting to Offer Medical Marijuana Recommendations to Patients 5Health News:Mercy College a “My Brother’s Keeper” Community 2Health News:Mercy College a “My Brother’s Keeper” Community 3Health News:OSF HealthCare Named One of the Most Wired Systems 2Health News:OSF HealthCare Named One of the Most Wired Systems 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 4Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 3
... important nutrients for the development of healthy nerves and ... among seniors, reports a new epidemiological study. ... USDA HNRCA, "we found a strong relationship between high ... and older who also had adequate levels of vitamin ...
... Cold Spring Harbor Laboratory (CSHL) have solved a decades-old ... suppressor gene, but have revealed// a master switch for ... effective cancer therapy in the future," said CSHL Associate ... was published in the February issue of Cell. ...
... study undertaken by a group of Spanish scientists, amongst ... University of Navarra and the Centre for Applied Medical ... a new line of treatment for patients with acute ... have been published in the official journal, Blood, of ...
... decade ago, Tom Todaro was talking to researchers at the Fred ... slow down tumor// growth by slowing the rate at which tumor ... not exploit the reaction in reverse and get cells to grow ... that has come up with techniques for increasing crop yields with ...
... suggests that strep infections in children may increase involuntary ... ,In an eight-month study of 693 children ... researchers found that shortly after the number of strep ... rise in involuntary movements and disruptive behaviors — symptoms ...
... thousands of doctors of Indian origin in Britain - many ... and gurudwaras - after they lost a case Friday against ... gain employment in the country's National Health Service (NHS). ... the prospect of returning home, while others waiting to find ...
Cached Medicine News:Health News:Optimum Folate and Vitamin B12 Levels Essential for Cognitive Function in Seniors 2Health News:Scientists Discover New Gene 2Health News:A New Treatment Discovered For Acute Lymphoblastic Leukemia 2Health News:Cancer Research May Help Biofuels 2Health News:Strep, Psychiatric Symptoms Possibly Linked in Some Children 2Health News:Strep, Psychiatric Symptoms Possibly Linked in Some Children 3Health News:Indian Doctors in Britain Lose Legal Battle 2Health News:Indian Doctors in Britain Lose Legal Battle 3Health News:Indian Doctors in Britain Lose Legal Battle 4
(Date:7/30/2015)...  Alimera Sciences, Inc. (NASDAQ: ALIM ) (Alimera), ... and commercialization of prescription ophthalmic pharmaceuticals, today announced that ... financial results after the market close on Monday, August ... the same day at 4:30 p.m. ET. ... Officer, and Rick Eiswirth , Chief Operating Officer ...
(Date:7/30/2015)... Minn. , July 30, 2015 EnteroMedics ... devices using neuroblocking technology to treat obesity, metabolic diseases ... host a conference call on Thursday, August 6, 2015, ... for the second quarter ended June 30, 2015, and ... Company,s vBloc® Neurometabolic Therapy, delivered via the Maestro® System. ...
(Date:7/30/2015)... July 30, 2015 Tissue ... the regenerative medical devices company, announces that it ... wound care market as Tissue Regenix Wound Care ... Medicare administrator, First Coast Service Options Inc. ("First ... , Puerto Rico and ...
Breaking Medicine Technology:Alimera Sciences To Release Second Quarter Fiscal Year 2015 Financial Results 2EnteroMedics to Host Second Quarter 2015 Financial Results and Company Update Conference Call 2EnteroMedics to Host Second Quarter 2015 Financial Results and Company Update Conference Call 3Tissue Regenix Group plc: First Coast Service Options Inc. Approves Medicare Coverage for DermaPure 2Tissue Regenix Group plc: First Coast Service Options Inc. Approves Medicare Coverage for DermaPure 3
... Nov. 23 Cumberland Pharmaceuticals Inc. ( CPIX) ... study evaluating the safety and efficacy of Caldolor ( ibuprofen ) ... was achieved for the primary endpoint of reducing fever in burn ... 61 adult burn patients with second or third degree burns covering ...
... , FORT WORTH, Texas, Nov. ... growing provider of specialty medical products, announced that it has filed it ... to illustrate the developments during the 2009 calendar year. , Q3 ... , Shareholder equity as of the Q3 2009 increased ...
Cached Medicine Technology:Caldolor(R) (Ibuprofen) Injection Demonstrates Significant Fever Reduction in Hospitalized Burn Patients 2Caldolor(R) (Ibuprofen) Injection Demonstrates Significant Fever Reduction in Hospitalized Burn Patients 3Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 2Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 3Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 4Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 5Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 6
... The Finnpipette Digital Multichannel, with ... lighter work of routine laboratory ... these advanced features: Soft-touch tip ... volume pipetting (0.5-10ul models), Entire ...
Inquire...
... And Impact2 Pipettors , , Available ... channel Impact and Impact2 pipettors can effectively ... with the same ergonomic design and superior ... are equally easy to program for a ...
... is ideal for all liquid handling applications ... operating buttons, and various dispensing techniques such ... make this a lab favorite. It intuitively ... pipette without any adverse effects on the ...
Medicine Products: